Crossmark

Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report

Crossref DOI link: https://doi.org/10.1186/s13019-019-0862-6

Published Online: 2019-03-04

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fiorelli, Alfonso http://orcid.org/0000-0002-0628-613X
Perrotta, Fabio

Mollica, Mariano

Santini, Mario

Vitiello, Fabiana

Gilli, Marina

Calabrese, Cecilia

Bianco, Andrea
License Information

Text and Data Mining valid from 2019-03-04
More Information

Article History

Received: 19 November 2018

Accepted: 17 February 2019

First Online: 4 March 2019

Ethics approval and consent to participate

: Patient signed an informed consent for the operation and was aware that his data could be used for scientific purpose.

: Patient was aware that his data could be used for scientific purpose.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below